Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Comparing Hydrocortisone and Prednisolone for Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD)

The goal of this cluster randomized controlled trial is to determine the optimal treatment for Acute Exacerbation of Chronic Obstructive Pulmonary Disease. The study compares the effects and side effects of hydrocortisone and prednisolone in patients above 40 years old diagnosed with chronic obstructive pulmonary disease with acute exacerbation. The main question is whether there is a difference in readmission for COPD excerbation or all cause mortality within thirty days. Participants will randomized to receive treatment with either hydrocortisone or prednisolone.

Participants needed: 2,000
Trial details
Phase: Phase 4Age: 40+Biological sex: AllType: InterventionalSponsor: Copenhagen Respiratory ResearchUpdated: Mar 18, 2026Locations: 14
Eligibility criteria

Age ≥40 years [+1]

All diagnoses that would merit treatment with a specific corticosteroid [+2]

Status: Recruiting

Comparing Hydrocortisone and Prednisolone for Community Acquired Pneumonia (CAP)

The goal of this cluster randomized controlled trial is to determine the optimal treatment for community aquired pneumonia (CAP). The study compares the effects and side effects of hydrocortisone and prednisolone in patients above 18 years old diagnosed with severe CAP. The main question is whether there is a difference in all cause mortality within thirty days. Participants will be randomized to receive treatment with either hydrocortisone or prednisolone.

Participants needed: 1,600
Trial details
Phase: Phase 4Age: 18+Biological sex: AllType: InterventionalSponsor: Copenhagen Respiratory ResearchUpdated: Mar 18, 2026Locations: 14
Eligibility criteria

Age > 18 years [+1]

Admitted >24 h [+4]

Status: Not yet recruiting

Local Antibiotic Delivery for Community Acquired Pneumonia

A randomized, double-blinded clinical pilot study to assess whether addition of inhaled levofloxacin 240 mg twice daily for three days leads to improved or worsened physiological status in CAP patients with and without pre-existing lung disease.

Participants needed: 36
Trial details
Phase: Phase 2, Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Copenhagen Respiratory ResearchUpdated: Mar 10, 2025
Eligibility criteria

Hospital admission within 24 hours. [+5]

Septic shock according to the sepsis III criteria:41 sequential organ failure as... [+12]